Analytical and Bioanalytical Chemistry

, Volume 408, Issue 3, pp 971–981 | Cite as

Fully automatic flow-based device for monitoring of drug permeation across a cell monolayer

  • Lucie Zelená
  • Sara S. Marques
  • Marcela A. Segundo
  • Manuel Miró
  • Petr Pávek
  • Hana SklenářováEmail author
  • Petr Solich
Research Paper


A novel flow-programming setup based on the sequential injection principle is herein proposed for on-line monitoring of temporal events in cell permeation studies. The permeation unit consists of a Franz cell with its basolateral compartment mixed under mechanical agitation and thermostated at 37 °C. The apical compartment is replaced by commercially available Transwell inserts with a precultivated cell monolayer. The transport of drug substances across epithelial cells genetically modified with the P-glycoprotein membrane transporter (MDCKII–MDR1) is monitored on-line using rhodamine 123 as a fluorescent marker. The permeation kinetics of the marker is obtained in a fully automated mode by sampling minute volumes of solution from the basolateral compartment in short intervals (10 min) up to 4 h. The effect of a P-glycoprotein transporter inhibitor, verapamil as a model drug, on the efficiency of the marker transport across the cell monolayer is thoroughly investigated. The analytical features of the proposed flow method for cell permeation studies in real time are critically compared against conventional batch-wise procedures and microfluidic devices.


Fully automated system Permeation study P-glycoprotein transporter Rhodamine 123 Sequential injection analysis 



The authors gratefully acknowledge the financial support of the Ministry of Education of the Czech Republic, project no. SVV 260 184, Grant Agency of the Charles University, project no. 159415, and the Grant Agency of the Czech Republic, project no. 15-10781S/P206. This work received financial support from the European Union (FEDER funds through COMPETE) and Portuguese National Funds (FCT, Fundação para a Ciência e Tecnologia) through project UID/Multi/04378/2013. M.M. is grateful to the Spanish Ministry of Science and Competitiveness for financial support through projects CTM2014-56628-C3-3-R and CTM2014-61553-EXP. Special thanks to Mgr. Lucie Hyršová for cell cultivation and kinetic profiles evaluation.

Compliance with ethical standard

Conflict of interest

The authors declare no conflict of interest.

Supplementary material

216_2015_9194_MOESM1_ESM.pdf (69 kb)
ESM 1 (PDF 68 kb)


  1. 1.
    Lai Y (2013) Transporter study methodologies. In: Transporters in drug discovery and development, detailed concepts and best practice. Woodhead Publishing Series in Biomedicine; Elsevier: AmsterdamGoogle Scholar
  2. 2.
    Zhang Y, Bachmeier C, Miller DW (2003) In vitro and in vivo models for assessing drug eflux transporter activity. Adv Drug Deliver Rev 55:31–51CrossRefGoogle Scholar
  3. 3.
    del Amo ME, Heikkinen AT, Mönkkönen J (2009) In vitro–in vivo correlation in P-glycoprotein mediated transport in intestinal absorption. Eur J Pharm Sci 36:200–211CrossRefGoogle Scholar
  4. 4.
    FDA Guidance for Industry (2012) Drug Interaction Studies—Study Design, Data Analysis, Implications for Dosing, and Labeling Recommendations, US Food and Drug Administration, Rockville. Available at: Accessed 20 March 2015Google Scholar
  5. 5.
    EMA Guideline on the investigation of drug interactions (2012) European Medicine Agency, London. Available at: Accessed 20 March 2015Google Scholar
  6. 6.
    Braun A, Hämmerle S, Suda K, Rothen-Rutishauser B, Günthert M, Krämer SD, Wunderli-Allenspach H (2000) Cell cultures as tools in biopharmacy. Eur J Pharm Sci 2(11Suppl):S51–S60CrossRefGoogle Scholar
  7. 7.
    Agarwal S, Jain R, Pal D, Mitra AK (2007) Functional characterization of peptide transporters in MDCKII-MDR1 cell line as a model for oral absorption studies. Int J Pharmaceut 332:147–152CrossRefGoogle Scholar
  8. 8.
    Hu HH, Bian YC, Liu Y, Sheng R, Jiang HD, Yu LS, Hu YZ, Zeng S (2014) Evaluation of blood–brain barrier and blood–cerebrospinal fluid barrier permeability of 2-phenoxy-indan-1-one derivatives using in vitro cell models. Int J Pharmaceut 460:101–107CrossRefGoogle Scholar
  9. 9.
    Fan Y, Rodriguez-Proteau R (2008) Ketoconazole and the modulation of multidrug resistance-mediated transport in Caco-2 and MDCKII-MDR1 drug transport models. Xenobiotica 38(2):107–129CrossRefGoogle Scholar
  10. 10.
    Lazar Arrow-M Micro Bioreactor System. Available at:, Accessed 25 June 2015
  11. 11.
    Anderson KB, Lockwood SY, Martin RS, Spence DM (2013) A 3D printed fluidic device that enables integrated features. Anal Chem 85:5622–5626CrossRefGoogle Scholar
  12. 12.
    Pasirayi G, Scott SM, Islam M, O’Hare L (2014) Low cost microfluidic cell culture array using normally closed valves for cytotoxicity assay. Talanta 129:491–498CrossRefGoogle Scholar
  13. 13.
    Růžička J, Marshall GD (1990) Sequential injection: a new concept for chemical sensors, process analysis and laboratory assays. Anal Chim Acta 237:329–343CrossRefGoogle Scholar
  14. 14.
    Ludescher C, Thaler J, Drach D, Drach J, Spitaler M, Gattringer C, Huber H, Hofmann J (1992) Detection of activity of P-glycoprotein in human tumour samples using rhodamine 123. Br J Haematol 82:161–168CrossRefGoogle Scholar
  15. 15.
    Fontaine M, Elmquist WF, Miller DW (1996) Use of rhodamine 123 to examine the functional activity of P-glycoprotein in primary cultured brain microvessel endothelial cells monolayers. Life Sci 59:1521–1531CrossRefGoogle Scholar
  16. 16.
    Wang Q, Yang H, Miller DW, Elmquist WF (1995) Effect of the P-glycoprotein inhibitor, cyclosporine A, on the distribution of rhodamine 123 to the brain: an in vivo microdialysis study in freely moving rats. Biochem Biophys Res Co 211:719–726CrossRefGoogle Scholar
  17. 17.
    Pavek P, Staud F, Fendrich Z, Sklenarova H, Libra A, Novotna M, Kopecky M, Nobilis M, Semecky V (2003) Examination of the functional activity of P-glycoprotein in the rat placenta barrier using rhodamine 123. J Pharmacol Exp Ther 305:1239–1250CrossRefGoogle Scholar
  18. 18.
    Hirsch-Ernst K, Ziemann C, Rustenbeck I, Kahl G (2001) Inhibitors of MDR1-dependent transport activity delay accumulation of the MDR1 substrate rhodamine 123 in primary rat hepatocyte cultures. Toxicology 167:47–57CrossRefGoogle Scholar
  19. 19.
    Yumoto R, Murakami T, Hasegawa R, Nagai J, Takano M (1999) Transport of rhodamine 123, a P-glycoprotein substrate, across rat intestine and Caco-2 cell monolayers in the presence of cytochrome P-450 3A-related compounds. J Pharmacol Exp Ther 289:149–155Google Scholar
  20. 20.
    Kim RB (2002) Drugs as P-glycoprotein substrates, inhibitors, and inducers. Drug Metab Rev 34(1/2):47–54CrossRefGoogle Scholar
  21. 21.
    Silva R, Vilas-Boas V, Carmo H, Dinis-Oliveira RJ, Carvalho F, De Lourdes BM, Remião F (2015) Modulation of P-glycoprotein efflux pump: induction and activation as a therapeutic strategy. Pharmacol Ther 149:1–123CrossRefGoogle Scholar
  22. 22.
    Varma MVS, Ashokraj Y, Dey CS, Panchagnula R (2003) P-glycoprotein inhibitors and their screening: a perspective from bioavailability enhancement. Pharmacol Res 48:347–359CrossRefGoogle Scholar
  23. 23.
    Lai Y (2013) P-glycoprotein (P-gp/MDR1)/ABCB1. In: Transporters in drug discovery and development, detailed concepts and best practice, Woodhead Publishing Series in Biomedicine; Elsevier: AmsterdamGoogle Scholar
  24. 24.
    Hämmerle SP, Rothen-Rutishauser B, Krämer SD, Günthert M, Wunderli-Allenspach H (2000) P-Glycoprotein in cell cultures: a combined approach to study expression, localisation, and functionality in the confocal microscope. Eur J Pharm Sci 12:69–77CrossRefGoogle Scholar
  25. 25.
    Miller JN, Miller JC (2005) Statistics and chemometrics for analytical chemistry. Upper Saddle River, NJ, Pearson/Prentice HallGoogle Scholar
  26. 26.
    Legnerova Z, Sklenarova H, Solich P (2002) Automated sequential injection fluorimetric determination and dissolution studies of ergotamine tartrate in pharmaceuticals. Talanta 58:1151–1155CrossRefGoogle Scholar
  27. 27.
    Klimundova J, Sklenarova H, Schaefer U, Solich P (2005) Automated system for release studies of salicylic acid based on a SIA method. J Pharm Biomed Anal 37:893–898CrossRefGoogle Scholar
  28. 28.
    Klimundova J, Mervartova K, Sklenarova H, Solich P, Polasek M (2006) Automated sequential injection fluorimetric set-up for multiple release testing of topical formulation. Anal Chim Acta 573(574):366–370CrossRefGoogle Scholar
  29. 29.
    Motz SA, Klimundova J, Schaefer UF, Balbach S, Eichinger T, Solich P, Lehr CM (2007) Automated measurement of permeation and dissolution of propranolol HCl tablets using sequential injection analysis. Anal Chim Acta 581:174–180CrossRefGoogle Scholar
  30. 30.
    Fortuna A, Alves G, Falcão A (2011) In vitro and in vivo relevance of the P-glycoprotein probe substrates in drug discovery and development: focus on rhodamine 123, digoxin, and talinolol. J Bioequiv Availab S2:1–24Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  • Lucie Zelená
    • 1
  • Sara S. Marques
    • 1
    • 2
  • Marcela A. Segundo
    • 2
  • Manuel Miró
    • 1
    • 3
  • Petr Pávek
    • 4
  • Hana Sklenářová
    • 1
    Email author
  • Petr Solich
    • 1
  1. 1.Department of Analytical Chemistry, Faculty of Pharmacy in Hradec KrálovéCharles University in PragueHradec KrálovéCzech Republic
  2. 2.UCIBIO, REQUIMTE, Department of Chemistry, Faculty of PharmacyUniversity of PortoPortoPortugal
  3. 3.FI-TRACE group, Department of ChemistryUniversity of Balearic IslandsPalma de MallorcaSpain
  4. 4.Department of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec KrálovéCharles University in PragueHradec KrálovéCzech Republic

Personalised recommendations